Adverse Events Compared for Gout Flare Prophylactic Drugs Adverse Events Compared for Gout Flare Prophylactic Drugs
Patients receiving prophylactic colchicine or NSAIDs with initiation of allopurinol for gout have more adverse events than those who receive no prophylaxis, but these events are rare overall.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - October 6, 2023 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news
Colchicine Still Needed in Allopurinol Up-Titration Strategy Colchicine Still Needed in Allopurinol Up-Titration Strategy
Patients taking colchicine had fewer gout flares than did those taking placebo for the first 6 months, but the number of flares evened out between the two groups over a 12-month period.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - September 11, 2023 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news
Allopurinol May Cut Risk for Neurodegenerative Diseases
FRIDAY, May 19, 2023 -- Xanthine dehydrogenase/oxidase blockers may reduce the risk for neurodegenerative diseases, according to a study published online May 17 in PLOS ONE.
Yizhe Song, from the Washington University School of Medicine in St. Louis,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 19, 2023 Category: Pharmaceuticals Source Type: news
Zydus gets US FDA final nod for Febuxostat tablets for treating high uric acid
According to the statement from Zydus, Febuxostat tablets are indicated to lower hyperuricemia (high uric acid in the blood) in patients with gout who have been treated with allopurinol that did not work well or cannot be treated with allopurinol. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 15, 2023 Category: Pharmaceuticals Source Type: news
Verinurad and Allopurinol in CKD Patients With Hyperuricemia Verinurad and Allopurinol in CKD Patients With Hyperuricemia
Learn more about the treatment effects of this combination therapy in patients with CKD and hyperuricemia.Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 5, 2022 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news
ALL-HEART: No Benefit of Allopurinol in Ischemic Heart Disease ALL-HEART: No Benefit of Allopurinol in Ischemic Heart Disease
Allopurinol failed to affect a composite of nonfatal MI, nonfatal stroke, or CV death, in a randomized trial that was ' definitively neutral ' in patients with heart disease but no gout.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - August 28, 2022 Category: Internal Medicine Tags: Cardiology News Source Type: news
Allopurinol Not Tied to Higher Mortality for Patients With Gout and CKD
TUESDAY, Jan. 25, 2022 -- For patients with gout and chronic kidney disease (CKD), no associations with increased mortality were seen for allopurinol initiation, achieving target serum urate (SU) levels, or allopurinol dose escalation, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 25, 2022 Category: Pharmaceuticals Source Type: news
Allopurinol Found Safe in Patients With Concomitant Gout, CKD Allopurinol Found Safe in Patients With Concomitant Gout, CKD
Despite earlier concerns, a study has found no sign of increased mortality with allopurinol therapy in patients with gout and chronic kidney disease.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - January 25, 2022 Category: Rheumatology Tags: Rheumatology News Source Type: news
No Reduction in WMH Progression With Allopurinol After Stroke No Reduction in WMH Progression With Allopurinol After Stroke
Use of allopurinol, a xanthine oxidase inhibitor, did not reduce progression of white matter hyperintensity (WMH) after stroke in a randomized trial.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - November 15, 2021 Category: Primary Care Tags: Neurology & Neurosurgery News Source Type: news
Allopurinol Proves Noninferior to Febuxostat for Gout Relief Allopurinol Proves Noninferior to Febuxostat for Gout Relief
A randomized, treat-to-target trial showed that the two urate-lowering therapies were comparably effective and safe at doses titrated to target, even among people with stage 3 chronic kidney disease.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 12, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news
Gout Pharmacotherapy in Cardiovascular Diseases Gout Pharmacotherapy in Cardiovascular Diseases
This review examines the utility of current gout therapies in the treatment and prevention of cardiovascular disease, including allopurinol, febuxostat, and colchicine.American Journal of Cardiovascular Drugs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 30, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Long-term improvement of aggression in a patient with schizophrenia using allopurinol as an adjuvant: a case report - Miyauchi T.
[The publisher has not provided an abstract for this article.]
Language: en... (Source: SafetyLit)
Source: SafetyLit - February 17, 2021 Category: International Medicine & Public Health Tags: Risk Factor Prevalence, Injury Occurrence Source Type: news
Indoco Remedies wins tenders worth Rs 140 crore for supply of kidney stones treatment drug in Germany
Aditi Kare Panandikar, Managing Director - Indoco Remedies said: "This is Indoco's first own label product in Europe. Germany is totally tender business and Indoco has won almost 80 - 85 per cent tenders for Allopurinol. This is a tender order for supplies spread over two years". (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 8, 2020 Category: Pharmaceuticals Source Type: news
Allopurinol and Mortality in Gout
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - November 22, 2020 Category: Orthopaedics Tags: Snapshot Source Type: news
Decline in Febuxostat Use Trends With Cardiovascular Concerns Decline in Febuxostat Use Trends With Cardiovascular Concerns
Allopurinol remains the first-line treatment, but it is not effective in all patients, and febuxostat was developed as an alternative.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - October 16, 2020 Category: Primary Care Tags: Rheumatology News Source Type: news
